TABLE 1.
TREATMENT ALLOCATION BY STUDY GROUP AND DEMOGRAPHIC CHARACTERISTICS OF PARTICIPANTS ENROLLED*
| Group 1 | Group 2 | Group 3 | Group 4 | Total (%) | |
|---|---|---|---|---|---|
| AERAS-402 treatment, n | 7 | 7 | 7 | 8* | 29 (72.5%) |
| Vaccine doses | 1 | 1 | 1 | 2 | |
| Vaccine dose (viral particles) | 3 × 108 | 3 × 109 | 3 × 1010 | 3 × 1010 | |
| Placebo treatment, n | 3 | 3 | 3 | 2 | 11 (27.5%) |
| Total treatment, n | 10 | 10 | 10 | 10* | 40 (100%) |
| Male, n | 4 (40%) | 6 (60%) | 4 (40%) | 3 (30%) | 17 (42.5%) |
| Age, median (min–max, yr) | 24.0 (22.0–38.0) | 26.0 (22.0–38.0) | 27.5 (22.0–39.0) | 27.0 (21.0–38.0) | 26.5 (21.0–39.0) |
| Ethnic group, n | |||||
| Black | 0 | 1 | 2 | 4 | 7 (17.5%) |
| Colored | 7 | 9 | 7 | 3 | 26 (65%) |
| White | 3 | 0 | 1 | 3 | 7 (16.5%) |
| BMI, mean (SD), kg/m2 | 24.8 ± 2.9 | 23.4 ± 3.4 | 24.1 ± 3.5 | 24.4 ± 2.9 | 24.2 ± 3.1 |
Definition of abbreviation: BMI = body mass index.
*
Two of eight participants did not meet eligibility criteria for revaccination.